Please provide your email address to receive an email when new articles are posted on . In a recent survey study, nearly 80% of physicians overestimated the probability of successful patient outcomes ...
Recent share price weakness is due to temporary headwinds, including client cost-cutting and delays in biotech decision-making, not structural issues in the CRO industry. Long-term prospects remain ...
New cancer therapies are frequently evaluated in multiple disease indications. We evaluated whether the probability of achieving US Food and Drug Administration (FDA) approval for a new cancer therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results